Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price dropped 6.1% on Monday . The company traded as low as GBX 4.55 ($0.06) and last traded at GBX 4.60 ($0.06). Approximately 745,412 shares changed hands during trading, a decline of 16% from the average daily volume of 883,358 shares. The stock had previously closed at GBX 4.90 ($0.06).
Allergy Therapeutics Price Performance
The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40. The stock’s fifty day moving average price is GBX 5.16 and its 200-day moving average price is GBX 3.66. The firm has a market cap of £219.42 million, a PE ratio of -76.67, a P/E/G ratio of -30.70 and a beta of 1.34.
Allergy Therapeutics Company Profile
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- How to Invest in Small Cap Stocks
- How to Invest in Silver: A Beginner’s Guide
- ETF Screener: Uses and Step-by-Step Guide
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- How Can Investors Benefit From After-Hours Trading
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
